A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors

Trial Details

NCT ID

NCT07354711

Phase

PHASE1 / PHASE2

Sponsor

3H Pharmaceuticals Co., Ltd.

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

• 3H-10000

Locations (sample)

• Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

• Subjects must be willing and able to sign the ICF and to adhere to the study visit schedule and other protocol requirements.
• Male or female subjects aged ≥18 years at the time of signing the ICF.
• According to RECIST v1.1, there is at least one measurable lesion.
• Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1 point.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.